BIOMAT Database Logo BIOMAT Database Logo

Dyslipidaemia: No effect of PCSK9 inhibitors on cognitive function. 2017

Irene Fernández-Ruiz

UI MeSH Term Description Entries
D007361 Intelligence Tests Standardized tests that measure the present general ability or aptitude for intellectual performance. Mental Tests,Raven Test,Raven's Progressive Matrices,Intelligence Test,Mental Test,Raven Progressive Matrices,Ravens Progressive Matrices,Test, Intelligence,Test, Mental,Test, Raven
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000091362 PCSK9 Inhibitors Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level. PCSK9 Inhibitors Cardiovascular,PCSK9 Inhibitors, Cardiovascular,Cardiovascular PCSK9 Inhibitors,Cardiovascular, PCSK9 Inhibitors,Inhibitors, Cardiovascular PCSK9
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D050171 Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. Dyslipoproteinemias,Dyslipidemia,Dyslipoproteinemia
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Irene Fernández-Ruiz
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors.
August 2018, European cardiology,
Irene Fernández-Ruiz
Role of PCSK9 inhibitors in the management of dyslipidaemia.
January 2024, Indian heart journal,
Irene Fernández-Ruiz
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
January 2016, Swiss medical weekly,
Irene Fernández-Ruiz
Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.
July 2017, Nature reviews. Cardiology,
Irene Fernández-Ruiz
Effects of PCSK9 inhibitors on platelet function.
March 2023, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,
Irene Fernández-Ruiz
Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
June 2015, Expert opinion on emerging drugs,
Irene Fernández-Ruiz
Just Price for PCSK9 Inhibitors: No less, No More.
November 2018, Journal of the American Heart Association,
Irene Fernández-Ruiz
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia.
December 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Irene Fernández-Ruiz
Dyslipidaemia: Anti-PCSK9 vaccines to halt atherosclerosis.
August 2017, Nature reviews. Cardiology,
Irene Fernández-Ruiz
No effect on cognitive function from daily mobile phone use.
February 2005, Bioelectromagnetics,
Copied contents to your clipboard!